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ABSTRACT 
Objective: To optimize the delay time before the initiation of arterial phase scan in the detection of focal liver 
lesions in contrast enhanced 5 phase liver CT using the bolus tracking technique. 
Patients and Methods: Delay - the interval between threshold enhancement of 100 hounsfield unit (HU) in the 
abdominal aorta and commencement of the first arterial phase scan. Using a 16 slice CT scanner, a plain CT of the liver 
was done followed by an intravenous bolus of 120 ml nonionic iodinated contrast media (370 mg I/ml) at the rate of 
4 mL/s. The second phase scan started immediately after the first phase scan. The portal venous and delay phases were 
obtained at a fixed delay of 60 s and 90 s from the beginning of contrast injection. Contrast enhancement index (CEI) 
and subjective visual conspicuity scores for each lesion were compared among the three groups. 
Results: 84 lesions (11 hepatocellular carcinomas, 17 hemangiomas, 39 other hypervascular lesions and 45 cysts) 
were evaluated. CEI for hepatocellular carcinomas appears to be higher during the first arterial phase in the 6 seconds 
delay group. No significant difference in CEI and mean conspicuity scores among the three groups for hemangioma, 
other hypervascular lesions and cysts. 
Conclusion: The conspicuity of hepatocellular carcinomas appeared better during the early arterial phase using a 
bolus tracking technique with a scan delay of 6 seconds from the 100 HU threshold in the abdominal aorta. © 2011 
Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Multiphase CT improves the sensitivity of liver 
lesions detection. MRI, despite being recognised to be 
superior in characterising focal liver lesions, remains a 
secondary tool due to limited resources in most centres in 
Malaysia. 
Approximately 30% of focal liver lesions are 
hypervascular and detectable exclusively on the arterial 
phases [1,2]. The early arterial phase of liver CT 
provides the best enhancement of hepatic arterial vessels 
and arterial-portal venous shunts [3]. Hypovascular liver 
metastases are most conspicuous on the portal venous 
phase [4,5]. Optimising the scan delay for the arterial 
phases is, therefore, important to improve the detection 
of hypervascular liver lesions. 
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Some researchers found triple-phase CT superior to 
dual-phase imaging in the detection and characterisation 
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Figure 1 Study design. 
 
of hepatocellular carcinoma (HCC) [1,6]. Foley et al. and 
Francis et al. found that hypervascular hepatic tumours 
are best enhanced on the late arterial phase with 24.5 to 
35 seconds delay from the initiation of contrast injection 
[7,8]. Murakami et al., however, recommended double 
arterial phase scan to improve the detection of 
hypervascular HCCs [9]. 
Other than the scan delay, the conspicuity of liver 
lesions are also affected by the lesion’s size, the patient’s 
body weight, cardiac output, blood pressure and pulse 
rate, the contrast volume, concentration and injection rate, 
and the scan parameters. This study aims to optimise the 
scan delay of contrast-enhanced 5-phase CT of the liver 
using a 16-slice MDCT and a bolus tracking technique to 
improve the detection of hypervascular liver lesions. 
PATIENTS AND METHODS 
This is a prospective study with approval from the 
ethical review committee, evaluating all patients who 
underwent 5-phase CT of the liver from February to 
October 2008 for suspected space occupying liver lesion 
based on clinical, laboratory or ultrasound findings. 
The inclusion criteria were: age above 15 years, 
serum creatinine of less than 1.5 mg/dL and no 
contraindications to iodinated contrast material. Patients 
were excluded based on several criteria which may affect 
liver vascularity, i.e. patients with diffuse liver lesions or 
lesion larger than 15 cm in diameter; previous 
radiofrequency ablation (RFA), transarterial 
chemoembolisation (TACE), percutaneous transhepatic 
cholangiography (PTC) or transjugular intrahepatic 
portosystemic shunt (TIPS); portal venous thrombosis, 
portal hypertension, hepatic venous thrombosis, inferior 
vena caval thrombosis or hepatic arterial portal shunt; 
technical failure related to contrast medium injection, 
breath-holding or machine problem during CT 
examination. 
All patients fasted for at least 6 hours prior to the 
CT examination. Contraindications to contrast injection 
were ruled out. Written informed consent was obtained. 
Patients were given 500 ml of plain water as oral contrast. 
An 18G branula was placed at the patients' antecubital 
vein. 
The study was performed using a GE Lightspeed 
16-MDCT scanner (Milwaukee, Wisconsin, USA) at the 
following settings: rotation time, 0.5 second; beam 
collimation, 16 × 0.625 mm; section thickness and 
intervals, 5.0 mm; pitch ratio, 1.375:1; table speed 
13.75 mm/s; scan time, 0.5 s, gantry tilt, 0.0; voltage, 
120 kVp; and tube current, 300 mAs. A bolus-tracking 
technique with automated scan-triggering software 
(SmartPrep, GE Healthcare) was used. A circular region 
of interest (ROI) was placed within the abdominal aorta 
just above the celiac axis level. The threshold CT value 
was preset at 100 HU. One of the three protocols with a 
scan delay of 3 seconds, 6 seconds or 9 seconds (from 
the time when threshold enhancement was detected to 
the beginning of the early arterial phase scan) was pre-
selected for each patient randomly prior to the 
examination. 
All patients underwent a non-contrast enhanced liver 
CT (Phase 1). A dual-syringe injector system (Stellant 
Medrad) was used for intravenous administration of 
120 ml non-ionic contrast media (Ultravist 370 mg I/mL) 
at 4 mL/s followed by 30–40 ml of saline chaser bolus. 
Real-time low-dose serial monitoring studies began 
13 seconds from the beginning of contrast injection. The 
early arterial phase scan (Phase 2) was triggered using 
one of the three scan protocols with a different time 
delay when the threshold enhancement was detected. 
Helical scan for the early arterial phase of the liver was 
performed in a cephalocaudal direction. The late arterial 
phase scan (Phase 3) started immediately following the 
early arterial phase scan, in a caudocephalic direction. 
The portal venous (Phase 4) and delayed scans (Phase 5) 
started at a fixed delay of 60 seconds and 90 seconds 
respectively, from the beginning of contrast injection. 
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Figure 2 The CT protocols for the 3 patient groups using the bolus tracking method with the scan delays of 3s, 6s and 9s. 
Patients were instructed to hold their breath in full 
inspiration during each scan phase (Figure 2). 
Post-processing images were reconstructed into a 
34–50 cm display FOV depending on the patients’ 
physique, at 1.250 cm sections and a window of 
400:40 HU. Image analysis was performed at a single 
workstation (Advantage Window 4.2, GE Healthcare) on 
an LCD monitor with a spatial resolution of 1280 × 1024 
pixels (Radiforce R22, Eizo). 
IMAGE ANALYSIS 
The conspicuity of each liver lesion was evaluated 
quantitatively and qualitatively on each scan phase. In 
patients with more than three lesions, the largest three 
lesions were assessed. 
Quantitative image analysis 
The attenuation of lesion was measured with a 
circular region of interest (ROI) by a radiologist who was 
blinded to the scan protocols, without changing the 
preset window (400:40 HU), with an attempt to maintain 
an ROI area of 50 mm2 at the centre or the most 
homogenously enhancing part of the lesion and with care 
to avoid regions of rim enhancement, tumour capsule, 
necrosis, calcifications or vessels. The attenuation of the 
background liver parenchyma was measured in two areas 
adjacent to the lesion and averaged, using a constant ROI 
area of 200 mm2, at least 1 cm away from the edge of the 
lesion to nullify the risk of encountering fibrosis [19], 
excluding visible vessels, bile ducts and artefacts. The 
conspicuity of a lesion was expressed using the Contrast 
Enhancement Index (CI): 
 
     
                                    
    
Lesion attenuation Average background liver
parenchymal attenuationCI
Average background liver parenchymal attenuation
−
=  
Qualitative image analysis 
Subjective assessment of lesion conspicuity was 
performed independently by three radiologists who were 
blinded to each other’s findings and with 30, 20 and 
6 years of experience in abdominal CT respectively, 
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Figure 3 Reference Images for grading visual conspicuity of lesions. Non-visualised lesions were graded 1; A poorly visualised lesion 
of grade 2 conspicuity (A); An adequately visualised lesion with poor margin delineation of grade 3 conspicuity (B); A lesion 
of grade 4 conspicuity with good delineation of almost the entire margin (C); A lesion of grade 5 conspicuity with clear 
demarcation of the entire margin (D). 
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Figure 4 The number and types of hypervascular lesions evaluated. 
 
using a 5-point scale based on a set of standard reference 
images (Figure 3). 
Statistical Analysis 
Statistical analysis was performed using SPSS 
version 17.0 and the non-parametric Kruskal-Wallis test 
to examine intergroup differences among the three scan 
protocols for both the CI and the conspicuity scores. A p 
value of less than 0.05 was considered to indicate a 
statistically significant difference. 
RESULTS 
Out of 197 patients who underwent 5-phase liver CT 
from February to October 2008, 120 were excluded 
(Table 1). 
Among the 77 patients who were included (40 male; 
37 female; age 15–90; mean age 59, SD 13.478), 39 
hypervascular liver lesions were evaluated (Figure 4). 
The diagnosis of each lesion was made with a consensus 
achieved among the three radiologists. 
Eleven HCC were evaluated: 4 from the 3-second 
delay group; 3 from the 6-second delay group; 4 from the 
9-second delay group. The CIs of HCC were highest in 
the 6-second delay group during the early arterial phase 
(p = 0.08) (Figure 5). The mean conspicuity scores of 
HCC were also higher in the 6-second delay group 
during both the arterial phases (p = 0.144, p = 0.465) 
(Figure 6). 
Seventeen liver hemangiomas were evaluated: 10 
from the 3-second delay group; 5 from the 6-second 
delay group; 2 from the 9-second delay group. The CIs 
of liver hemangiomas were higher in the 3 seconds delay 
group during the early arterial & late arterial phases 
(p = 0.824, p = 0.163) (Figure 7). The mean conspicuity 
scores of liver hemangiomas were also higher in the 3-
second delay group during both the arterial phases 
(p = 0.093, p = 0.033) (Figure 8). 
The other hypervascular liver lesions which include 
focal nodular hyperplasia (FNH), the non-specific benign 
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Figure 5 Box and whisker plot illustrating CI for HCC during different scan phases. 
 
 
 
Figure 6 Mean conspicuity scores for HCCs during different scan phases. 
 
hypervascular lesions and the hypervascular metastases, 
were analysed together. There were 5 hypervascular 
lesions in the 3-second group, 2 in the 6-second group 
and 4 in the 9-second group. The CI was highest in the 3-
second group during the early arterial phase (p = 0.499) 
(Figure 9). The mean conspicuity scores for these 
hypervascular liver lesions are higher in the 3-second 
group during both the early arterial and late arterial 
phases (p = 0.524, p = 0.179) (Figure 10). 
DISCUSSION 
The automated bolus tracking technique has been 
widely recognised to be superior to the fixed-time delay 
technique in multiphase liver CT, by allowing 
individualisation and better timing of the scan delay [10–
17]. However, in the authors’ institution, five-phase 
dynamic CT of the liver has been routinely performed 
using a fixed-time delay technique for the investigation, 
and follow-up of suspected and known liver lesions. This 
study aimed to determine the optimal scan delay using 
the bolus tracking technique for the detection of 
hypervascular liver lesions. 
The three scan protocols using 3-second, 6-second 
and 9-second scan delays represent an actual delay time 
of 6 seconds, 9 seconds and 12 seconds, respectively, 
from the time when threshold enhancements (100 HU) 
were detected. These protocols were designed based on a 
previous study by Myeong-Jin Kim et al., which 
suggested a scan window of 14 to 30 seconds from a 
100 HU threshold in the abdominal aorta at the celiac 
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Figure 7 Box and whisker plot illustrating CI for liver haemangioma during different scan phases. 
 
 
 
Figure 8 Mean conspicuity scores for liver hemangiomas during different scan phases. 
 
axis level for the detection of hypervascular HCCs. In 
their study, the duration of each phase scan was 4.5–
8.8 seconds and the second arterial phase scan started 
6 seconds after the end of the early scan [13]. Therefore, 
the beginning of the early arterial phase scan ranges from 
3.5 seconds to 15.2 seconds from the 100 HU threshold 
in the abdominal aorta. 
In our study, the CIs for HCCs were significantly 
higher during the early arterial phase scan in the 6-
second delay group (p = 0.08). Correspondingly, the 
mean conspicuity scores for HCCs were highest in the 6-
second delay group during both the arterial phases. 
Given a small sample size of 11 HCCs, a p value of 0.08 
inferred a statistically significant difference in a larger 
study population. 
An optimal temporal window of 36–56 seconds in 
arterial phase imaging had been suggested by Lee et al. 
for the detection of HCC using a single-detector CT. 
Frederick et al. suggested a temporal window of less than 
45 seconds for the detection of hypervascular lesions 
[13]. Several other studies on double arterial phase CT 
using a 4-slice CT found either one of the early or late 
arterial phase images to be too early or too late for 
optimal depiction of hypervascular HCCs [7,9,13]. In a 
study using a 16-slice CT, biphasic arterial phase scan 
and bolus tracking technique, the optimal scan window 
in arterial phase imaging for the detection of 
Chan et al. Biomed Imaging Interv J 2011; 7(2):e12  7 
  This page number is not 
  for citation purposes 
 
Figure 9 Box and whisker plot illustrating CI for the other hypervascular lesions during different scan phases. 
 
 
 
Figure 10 Mean conspicuity scores for the other hypervascular lesions during different scan phases. 
 
hypervascular HCC was found to be 14–30 seconds from 
100 HU threshold in the abdominal aorta at the celiac 
axis level [13] In our 6-second delay protocol, the actual 
temporal delay for the first arterial phase scan was 
9 seconds from the 100 HU threshold in the abdominal 
aorta at the celiac axis level, which was slightly earlier 
than the temporal window of 14 to 30 seconds suggested 
by Myeong-Jin Kim et al. [13]. 
The injection protocols in the two studies were very 
similar. In the previous study, the contrast dose was 
adjusted according to body weight [13]. However, a 
standard injection protocol was applied in our study 
regardless of patient’s body weight. This is to avoid 
calculation error in contrast dosage in the setting of a 
busy radiology department. To overcome the potential 
limitation caused by contrast dosing on the time to peak 
enhancement, a relatively high volume (120 ml) and high 
concentration (370 mg I/ml) contrast media was used. 
The volume of 120 ml and concentration of 370 mg I/mL 
consisted of 44,400 mg Iodine, which was equivalent to 
an iodine dose of 525 mg/kg in an 84 kg patient or 
888 mg/kg in a 50 kg patient. In the study by Yumi 
Yanaga et al. on the optimal contrast dose for depiction 
of hypervascular HCCs, administration of 450 mg I/kg 
body weight was considered adequate and a total iodine 
dose of 525 mg I/kg body weight was considered 
desirable for excellent depiction of hypervascular HCC 
[18]. Our injection protocol was adequate to provide a 
desirable iodine dose in a patient of up to 84 kg in body 
weight. 
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Table 1. Reasons for patient exclusion. 
Reasons for patient exclusion Number of patients 
TACE 
RFA 
Portal hypertension, thrombosis of portal vein, hepatic vein or vena cava 
Hepatectomy 
RFA & TACE 
Diffuse lesions or lesions > 5cm in size 
RFA & surgery 
PTC 
Liver failure 
RFA & portal hypertension or portal venous thrombosis 
RFA & arterioportal shunt 
TACE & surgery 
TACE & portal venous thrombosis 
Transjugular intrahepatic portosystemic shunt & portal hypertension 
RFA & TACE & surgery 
RFA & TACE & portal venous thrombosis 
Technical error 
27 
24 
14 
11 
10 
4 
3 
1 
1 
1 
1 
1 
1 
1 
1 
1 
18 
Total  120 
 
High speed injections of up to 7 ml/s had been used 
in a study on HCC using dynamic 16-MDCT in cine 
mode by Xiaozhou Ma et al. [19] and an injection rate as 
high as 10 ml/s had been used by Bader et al. in a liver 
perfusion study. However, a moderate injection rate at 
4 ml/s, which was applied in this study, has been 
accepted by many researchers [16] in order to avoid 
patients’ discomfort and to reduce the risk of 
extravasation. The authors also believe that the high 
iodine concentration of 370 mg I/mL was able to 
compensate for the moderate injection rate in achieving 
adequate conspicuity of hypervascular liver lesions. 
The higher CIs of liver hemangiomas in the 3-
second delay group corresponded with the higher mean 
conspicuity scores in the same group during both the 
arterial phases. The lack of statistical significance of 
these results may be explained by an unequal patient 
distribution among the three groups which had occurred 
by chance during random assignment of patients into one 
of the three groups prior to the CT examinations. There 
were 10 out of 17 patients (59%) with liver 
hemangiomas in the 3-second delay group, 5 patients 
(29%) in the 6-second delay group and only 2 patients 
(12%) in the 9-second delay group. The significantly 
larger sample number in the 3-second delay group 
compared to the other two groups could have skewed the 
results to the more favourable CIs and mean conspicuity 
scores in this group. 
Data pooling aims to increase the statistical power in 
the outcome of analysis. All hypervascular lesions other 
than HCCs and the classical hemangiomas were 
evaluated as a group in view of the small number of each 
of these lesions, which include the FNHs, the non-
specific benign hypervascular lesions and the 
hypervascular metastases. The higher CIs of these 
lesions which were observed in the 3-second delay group 
may again be attributed to the unequal patient 
distribution, of which the majority (45%) was in the 3-
second delay group. 
In this study, nine out of eleven HCCs were 
diagnosed on CT, out of which four were further 
supported by elevated serum AFP levels and one by 
characteristic MRI findings. Another tumour nodule of 
2 cm was diagnosed based on characteristic CT findings, 
a history of chronic hepatitis B with cirrhosis and an 
abnormal AFP level. Only one tumour was diagnosed by 
histopathology examination. According to the American 
Association for the Study of Liver Diseases (AASLD) 
guidelines [20] and the unpublished consensus of the 
European Association for the Study of the Liver experts 
[21], a diagnosis of HCC can be made when the 
characteristic HCC profile of intense arterial uptake 
followed by contrast washout in delayed venous phase is 
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observed in a nodule larger than 2 cm with a cirrhotic 
liver on a single dynamic imaging technique or on two 
dynamic imaging techniques in nodules between 1 and 
2 cm [20,21]. The Asian Oncology Summit in 2009 
recommended diagnosis of HCC based on characteristic 
image on dynamic CT or MRI regardless of tumour size 
without tissue biopsy (limited-resource level, level 2a 
evidence). The sensitivity and specificity of dynamic CT 
in the diagnosis of HCC was 68% (95% CI 55–80%) and 
93% (89–96%); 81% (70–91%) and 85% (77–93%) for 
dynamic MRI, compared with pathological examination 
as the reference standard [22]. Although a normal serum 
AFP concentration (10–20 ng/mL) has been observed in 
20% of HCC patients, an AFP concentration 
> 400 ng/mL in a patient with liver cirrhosis or chronic 
hepatitis (basic-resource level, level 2a evidence) [22] 
and a mass larger than 2 cm in a patient with an 
AFP > 200 ng/dL are considered diagnostic of HCC [23]. 
A 1–3% risk of tumour seeding during liver biopsy has 
been reported. Biopsy of potentially operable lesions 
should therefore be avoided (limited-level resource, level 
2a evidence) unless a major diagnostic doubt cannot be 
resolved with dynamic imaging and measurement of 
AFP concentration (evidence grade IIa, recommendation 
grade B) [22, 24]. Tumour location preventing needle 
insertion, clotting disorders, ascites and false-negative 
results caused by sampling error or unfeasibility of 
confidently distinguishing between dysplastic changes 
and well-differentiated HCC are other recognised 
limitations of needle biopsy [21]. 
Liver hemangiomas were diagnosed based on the 
classical hypodensity similar to that of vessels on non-
enhanced CT, peripheral globular enhancement isodense 
to that of the aorta during the arterial phases followed by 
centripetal fill-in pattern similar to those of the blood 
pool during the portal venous phase [25]. FNHs were 
characterised by hypervascularity during the arterial 
phases and isodensity in the portovenous and delayed 
phases. There were five lesions which did not meet the 
imaging diagnostic criteria of haemangioma or FNH and 
were unchanged on follow-up imaging. We labelled 
these lesions as non-specific benign hypervascular 
lesions. These may represent an atypical haemangioma, 
FNH or, less commonly, an adenoma. A definitive 
histopathological diagnosis was not sought because of 
their benign nature. 
In this study, the three different CT protocols which 
were performed in three patient groups were compared, 
where the results may be affected by inter-individual 
variability among the different groups of patients. 
However, repeating the CT examination in the same 
patients without clear clinical indication is non-
justifiable due to the large radiation dose to patient. 
The biggest limitation of this study was the small 
sample size of each lesion group despite an acceptable 
size of sample population, especially for the HCC group. 
Almost all patients with HCCs underwent treatment 
which potentially altered liver vascularity prior to a 
follow-up imaging which made them no longer eligible 
for the study (85%, 112 out of 120). For patients with 
hemangiomas or other benign lesions, follow-up imaging 
by ultrasound was preferable rather than CT or MRI. 
Lesions larger than 15 cm were excluded in view of 
the fact that larger size lesions may affect liver 
vascularity. However, further analysis of data based on 
lesion’s size, body weight and other factors was not 
carried out, which may affect the conspicuity of liver 
lesions due to a small study sample, which is also a 
limitation in this study. 
Thirdly, the lack of pathological proof in lesion 
diagnoses could be a potential limitation. Exclusion of 
atypical HCCs or hemangiomas, inclusion of non-HCC 
hypervascular lesions into the HCC group and inclusion 
of non-haemangiomas into the haemangioma group had 
been possible. 
Finally, the patients in this study were not classified 
based on the degree of tumour angioinvasion, 
background cirrhosis, liver function status and fatty 
infiltration, which may potentially affect the 
enhancement pattern and the conspicuity of liver lesions. 
CONCLUSION 
The conspicuity of hypervascular HCCs seemed to 
be better on images obtained during the early arterial 
phase by using a bolus tracking technique with a scan 
delay of 6 seconds from the 100 HU threshold in the 
abdominal aorta at the celiac axis level, i.e. 9-second 
delay from the initiation of contrast injection. To 
compare this with delays of 15–30 seconds would 
require further studies as this imaging is protocol-driven. 
In keeping with minimising the radiation dose, it is 
proposed to exclude the pre-contrast phase. To exclude 
the delayed phase of imaging would require a larger 
group to be evaluated. 
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